[1] Mullard A., 2013 FDA Drug Approvals, Nat. Rev. Drug. Disco., 13 (2): 85-9 (2014).
[4] Becker M.S., Schmezer P., Breuer R.,
Haas S.F.,
Essers M.A.,
Krammer, P.H.,
Li-Weber, M.,
The Traditional Chinese Medical Compound Rocaglamide Protects Nonmalignant Primary Cells from DNA Damage-Induced Toxicity by Inhibition of p53 Expression,
Cell. Death. Dis.,
5 (1): e1000 (2014).
[13] Ratke C., Pawar P.M., Balasubramanian V.K., Naumann M., Duncranz M.L., Derba-Maceluch M., Gorzsas A., Endo S., Ezcurra I., Mellerowicz E.J.,
Populus GT43 Family Members Group Into Distinct Sets Required for Primary and Secondary Wall Xylan Biosynthesis and Include Useful Promoters For Wood Modification,
Plant. Biotechnol. J.,
13(1): 26- (2015).
[16] Li H., Huang Y., Yuan J., Yang G., Synthesis and Characterization of Cross-Linked Graft Copolymer of Acrylamide/Methyl Methacrylate onto Bagasse xylan, New. Chemical. Materials (China)., 42 (10): 199-201 (2014).
[19] Zhang Y., Li H.L., Wang H.P., Gu J., Ma C.L., Wu H.Y., Effects of Ferulic Acid on Gastric Cancer Cell Line MGC-803 Proliferation, Chin. J. Inf. TCM., 23(9): 70-73 (2016).
[22] Morris G., “SYBYL-X 2.0”, Tripos Associates, St Louis (